CCA-3'; SEQ ID NO:16), CRR1 (5'-CTTGGGCAGAACCACGGAAGCTACC-3'; SEQ ID NO: 17), RTF1 (5'-GATGTTTGTATGGATCCTCAGCCCA-3'; SEQ ID NO: 18) and RTR1 (5'GCCGAACAATGGTTGTAA CAAAAGG-3'; SEQ ID NO: 19).

Please amend the Claims as Follows:

Claim 41 (Amended) An oligonucleotide selected from the group consisting of:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEQ ID NO: 12),

LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEQ ID NO: 13),

LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEQ ID NO: 14), or

LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEQ ID NO: 15).

A marked-up copy of the specification and claim amendments are provided in Appendix A.

REMARKS

The present submission is in response to the Official communication dated February 5, 2002 enclosing a Notification Of Missing Requirements Under 35 U.S.C. §371 In The United States Designated/Elected Office in connection with the above-identified patent application.

To comply with the requirements under 37 C.F.R. §§1.821-1.825, submitted herewith is a sequence listing of the nucleotide sequences presented in the above-referenced application. The sequence listing is being submitted in both paper copy and computer-readable form. Applicants respectfully request entry of the sequence listing into the above-identified patent application. The undersigned hereby verifies that the paper copy and computer readable form of the sequence listing are identical and do not contain any new matter.

In addition, the specification and Claim 41 have been amended herewith to include the sequence identifiers (SEQ ID NO'S) for the sequences appearing in the text of the above-

identified application.

In the event that a fee is required, the Commissioner is authorized to charge the account of the undersigned, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By Patrick J. Hagan
Patrick J. Hagan
PTO Registration No. 27,643

Telephone: (215) 563-4100

Enclosure: Appendix A

Appendix A

(Page 31, Line 1) Site directed mutagenesis of ricin toxin B chain gene. Four mutagenic oligonucleotides were used in PCR reactions to create an EcoRI and a HindIII restriction site at selected positions along the ricin toxin B chain gene in the plasmid pWT (Wales et.al., 1991) - these are shown in Fig 1A. The five mutagenic oligonucleotides (mutated bases underlined) were:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEQ ID NO: 12)
LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEQ ID NO: 13)
LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEQ ID NO: 14)
LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEQ ID NO: 15)

(Page 43, Line 34) Total RNA was extracted from 100 mg leaf tissue of transformed and wild type rice plants using the RNeasy Plant Mini kit (Qiagen) according to the supplier's recommendations. RT-PCRs were carried out using the Access-PCR kit (Promega) according to the manufacturer's instructions. We used 100 ng total RNA and 50 pmol of each primer. Primers CRF1 and CRR1 amplify both *cry1Ab* and *cry1Ac*, while primers RTF1 and RTR1 amplify the RTB gene fragment. The primer sequences were as follows: CRF1 (5'-CGCATTGAAAC CGGTTACACTC CCA-3'; SEQ ID NO:16), CRR1 (5'-CTTGGGCAGAACCACGGAAGCTACC-3'; SEQ ID NO: 17), RTF1 (5'-GATGTTTGTATGGATCCTCAGCCCA-3'; SEQ ID NO: 18) and RTR1 (5'GCCGAACAATGGTTGTAA CAAAAGG-3'; SEQ ID NO: 19).

Claim 41 (Amended) An oligonucleotide selected from the group consisting of:
LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEQ ID NO: 12),
LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEQ ID NO: 13),
LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEQ ID NO: 14), or
LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEQ ID NO: 15).